Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities

Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a strong emphasis on prevention, early detection, and locally driven solutions.

Pilot Results Show Dramatic Health Gains

Real-world outcomes from existing programs demonstrate the power of targeted, community-embedded care. In rural Vietnam, the Community Health Initiative screened 400,000 people, linked 35,000 to treatment, and more than doubled hypertension control rates from 32% to 76%. Diabetes control rates nearly tripled from 27% to 77%. The CARDIO4Cities model, which uses real-time data and artificial intelligence, has achieved three- to six-fold increases in hypertension control within one to two years, along with measurable reductions in strokes and heart attacks.

Inclusive Health Accelerators Target U.S. Cancer Disparities

In the United States, Novartis is launching Inclusive Health Accelerators in New York, Los Angeles, Detroit, Houston, and Baltimore. These programs focus on closing detection gaps for breast and prostate cancer through community education, free screenings, and streamlined referrals to specialist care.

Three Distinct Models, One Shared Philosophy

Each program is built on local health system strengthening rather than traditional commercial channels. CARDIO4Cities relies on data-driven municipal planning, while Community Health Initiatives in low- and middle-income countries emphasize direct outreach and decentralized treatment. The U.S.-based Inclusive Health Accelerators leverage partnerships with community organizations and health authorities. All three models share a core principle: Novartis collaborates with governments, nonprofits, and local stakeholders to co-create sustainable solutions that address structural barriers.

Strategic Value for Evidence Generation and Market Access

The documented improvements in hypertension control and projected reductions in cardiovascular events provide a strong foundation for real-world evidence generation. These findings can demonstrate the cost-effectiveness of upstream community interventions. By operating across both global and domestic markets, Novartis is building a diverse evidence portfolio that speaks to population-level impact.

This expansion of community health programs represents a deliberate shift toward shared-value models that improve brand perception and stakeholder relationships while delivering measurable clinical benefit. As health systems grapple with rising chronic disease burdens, these initiatives offer a practical, evidence-based blueprint for scalable change.